Praveen Ramakrishnan Geethakumari
Overview
Explore the profile of Praveen Ramakrishnan Geethakumari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
252
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Farooq F, Brandt J, Cardonick E, Polushkina E, Vose J, Ahmed S, et al.
Blood Adv
. 2023 Jun;
7(18):5480-5484.
PMID: 37259563
No abstract available.
12.
Epperla N, Welkie R, Torka P, Shouse G, Karmali R, Shea L, et al.
J Hematol Oncol
. 2023 May;
16(1):49.
PMID: 37158890
Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not...
13.
Hoff F, Chung S, Patel P, Premnath N, Khatib J, Tadic-Ovcina M, et al.
Transpl Immunol
. 2023 Feb;
77:101808.
PMID: 36842566
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option for high-risk myeloid malignancies. Post-transplant cyclophosphamide (PT-Cy) has proven to be effective for graft versus host disease (GVHD)...
14.
Chavez J, Foss F, William B, Brammer J, Smith S, Prica A, et al.
Clin Cancer Res
. 2023 Feb;
29(10):1869-1878.
PMID: 36826995
Purpose: Proliferation of T-follicular helper (TFH) CD4+ T cells is a postulated pathogenic mechanism for T-cell non-Hodgkin lymphomas (T-NHL). The inducible T-cell costimulator (ICOS) is highly expressed by TFH, representing...
15.
Kapinos K, Hu E, Trivedi J, Ramakrishnan Geethakumari P, Kansagra A
Cancer Control
. 2023 Jan;
30:10732748221142945.
PMID: 36651055
Objectives: Among advanced multiple myeloma (MM) patients, B-cell maturation antigen (BCMA) specific targets like Belantamab Mafodotin (belamaf) and CAR T-cell therapies have been shown to improve clinical outcomes, but at...
16.
Premnath N, Chung S, Weinberg O, Ikpefan R, Pandey M, Kaur G, et al.
Leuk Res
. 2022 Dec;
125:107001.
PMID: 36566538
Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote...
17.
Oertling E, Fuda F, Koduru P, Chen M, Weinberg O, Juntilla M, et al.
Leuk Res
. 2022 Dec;
124:106995.
PMID: 36459761
No abstract available.
18.
Optimizing Palliative Focal Radiation Therapy Dose in Cutaneous T-Cell Lymphoma: How Low Can You Go?
Patel A, West L, Atluri P, Yi S, Rizvi S, Ramakrishnan Geethakumari P, et al.
Pract Radiat Oncol
. 2022 Oct;
13(2):e192-e199.
PMID: 36307013
Purpose: Primary cutaneous T-cell lymphomas (CTCLs) are radiosensitive tumors with variable and often relapsing courses. Local disease can be treated with low-dose focal palliative radiation therapy (RT), though little data...
19.
Epperla N, Zhao Q, Chowdhury S, Shea L, Moyo T, Reddy N, et al.
Blood Adv
. 2022 Oct;
7(1):88-91.
PMID: 36269847
No abstract available.
20.
Hamdan H, Luu L, Opsahl M, Weinberg O, Fuda F, Koduru P, et al.
Cytometry B Clin Cytom
. 2022 Sep;
102(6):448-450.
PMID: 36102633
No abstract available.